The Magazine Coping with Cancer has a nice piece this month on emerging treatments for Non-Hodgkins Lymphoma; you can access the online version of the article here.
I don't think there's anything startlingly new here, but it's a good review of what's going on in NHL treatment right now. Some of my pals are mentioned: Velcade, which works by causing cancer cells to poison themselves; Bendamustine/Treanda, an advanced chemotherapy with much less toxicity and fewer side effects than most other NHL chemos; Biovax, the NHL vaccine that seems to be finally living up to its promise; and, of course, my intimate friend Rituxan -- my NHL BFF, if you will.
I like these review articles, even if I'm already aware of all of the information that's being given. They're a good reminder of how many treatment possibilities exist now, and how many very promising ones are in the pipeline --- even a fraction of them end up being an improvement on what's available now, that's a great thing.
Speaking of the Biovax vaccine: a presentation at the ASH conference showed some additional good news. I can't find it right now, but I will, and I'll post soon.
No comments:
Post a Comment